Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.

Jacob RF, Walter MF, Self-Medlin Y, Mason RP.

J Cardiovasc Pharmacol. 2013 Aug;62(2):160-6. doi: 10.1097/FJC.0b013e318294998d.

PMID:
23575262
3.

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.

Aviram M, Rosenblat M, Bisgaier CL, Newton RS.

Atherosclerosis. 1998 Jun;138(2):271-80.

PMID:
9690910
4.

Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.

Mason RP, Walter MF, Day CA, Jacob RF.

J Biol Chem. 2006 Apr 7;281(14):9337-45. Epub 2006 Feb 7.

5.

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.

Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.

Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97.

6.

Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.

Sezer ED, Sozmen EY, Nart D, Onat T.

Vasc Health Risk Manag. 2011;7:333-43. doi: 10.2147/VHRM.S17781. Epub 2011 Jun 1.

7.

Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.

Takagi H, Niwa M, Mizuno Y, Yamamoto H, Goto SN, Umemoto T.

Heart Vessels. 2014 May;29(3):287-99. doi: 10.1007/s00380-013-0358-6. Epub 2013 May 5. Review.

PMID:
23644555
8.

Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.

Mason RP, Jacob RF.

Biochim Biophys Acta. 2015 Feb;1848(2):502-9. doi: 10.1016/j.bbamem.2014.10.016. Epub 2014 Oct 22.

9.
10.

The clinical relevance of low-density-lipoproteins size modulation by statins.

Rizzo M, Berneis K.

Cardiovasc Drugs Ther. 2006 Jun;20(3):205-17. Review.

PMID:
16775666
11.

Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.

Kucera M, Oravec S, Hirnerova E, Huckova N, Celecova Z, Gaspar L, Banach M.

Angiology. 2014 Oct;65(9):794-9. doi: 10.1177/0003319713507476. Epub 2013 Oct 24.

PMID:
24163116
13.

The effects of atorvastatin on oxidative stress in L-NAME-treated rats.

Sozer V, Uzun H, Gelisgen R, Kaya M, Kalayci R, Tabak O, Arican N, Konukoglu D.

Scand J Clin Lab Invest. 2013 Oct;73(7):591-7. doi: 10.3109/00365513.2013.828241. Epub 2013 Sep 12.

PMID:
24024670
14.

Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.

Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, Creager MA.

Circ Res. 2004 Jul 23;95(2):217-23. Epub 2004 Jun 3.

15.

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600.

16.

Effects of atorvastatin on the different phases of atherogenesis.

Rubba P.

Drugs. 2007;67 Suppl 1:17-27. Review.

PMID:
17910518
17.
18.

The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.

Mulder DJ, van Haelst PL, Wobbes MH, Gans RO, Zijlstra F, May JF, Smit AJ, Tervaert JW, van Doormaal JJ.

Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7. Epub 2007 Mar 7.

19.

Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.

Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, Derdák Z, Illyés L, Paragh G.

Transl Res. 2009 Apr;153(4):190-8. doi: 10.1016/j.trsl.2009.01.007. Epub 2009 Feb 14.

PMID:
19304278
20.

Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.

Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, Taira T, Adachi M.

Metabolism. 2004 Sep;53(9):1113-7.

PMID:
15334369

Supplemental Content

Support Center